Hypertrophic cardiomyopathy in the young: Another form of ischemic cardiomyopathy?  by Botvinick, Elias H. et al.
JACC Vol . 22, No . 3
September 1993 :8 05 -7
Editorial Comment
11ype.1rv§'!_'_- Cor ~i~zm~jy
I
	
I I the L
~ Anothel-c
- Fon-i
Ischenk Carrldllomyopathy?*
ELIAS H . BOTVINICK, MD, FACC,
MICHAEL W. DAE, MD,
RAJAGOPAL KRISHNAN, MD,
STANFORD EWING, MD
San Francisco, Caliji)rnia
The condition. Hypertrophic cardiomyopathy is a patho-
physiologic lesson to the student, a frequent diagnostic and
therapeutic dilemma for the clinician and always a potential
threat to the prtient. A mixed model of interacting mecha-
nisms, the entity rests in the shadows of our knowledge,
challenging the physician of each generation . Testimony to
our insecurity with the condition is given by its several prior
aliases including idiopathic hypertrophic subaortic stenosis
(IHSS) and asymmetric septal hypertrophy (ASH) . In this
issue of the Journal, Dilsizian and coworkers (1) help to
move the condition further into the light .
An important clinical relationship . The proposed relation-
ship between myocardial ischemia and syncope or cardiac
arrest in young patients with hypertrophic cardiomyopathy
has been suggested by prior studies, many of which have
been contributed by coworkers of Dilsizian (2,3) . It is well
documented in the present study (1) by c,-mpelling clinical
analysis .
Sudden death in bypertrophic cardiomyopathy . In adults .
A minority of adults with hypertrophic cardiomyopathy die
of heart failure or systemic embolism. Most of these die
suddenly (4) . Sudden death affects 200,000 to 400,000 adults
each year, accounting for approximately 15% to 20% of
deaths among adult Americans (5) and for 2% to 20% of
nontraumatic deaths in patients aged I to 20 years (6,7) .
Hypertrophic cardiomyopathy is present in a significant
fraction of both groups of subjects with sudden death (3) .
Many patients with hypertrophic cardiomyopathy have evi-
dence of sinoatrial dysfunction or supraventricular tachycar-
dia
; the latter is often poorly tolerated in these patients (4)
.
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Nonsustained ventricular tachycardia on Holter ambulatory
electrocardiographic (ECG) monitoring (8,9) and electro-
physiologic study (5,8), family history of sudder, death 110)
and prior syncope (11,12) are risk factors for sudden death
among adults with hypertrophic cardiomyopathy
. A more
general relationship has been established among syncope,
low ventricular filling volume, nonsustained ventricular
tachycardia and, by implication, any sudden increase in
heart rate (12) . This pattern parallels the clinical pattern of
effort-related symptoms. Although some studies have shown
contrasting findings (8), no hemodynamic measure, including
the severity of left ventricular outflow tract obstruction
(11,13) or the magnitude of left ventricular filling pressures,
can predict sudden death in obstructive cardiomyopathy
.
The degree of related left ventricular hypertrophy and of
functional left ventricular impairment, and results of the
signal-averaged electrocardiogram have been associated in
some studies with the occurrence of sudden death (11, 14) .
Holier ambulatory ECG evidence of ventricular tachycar-
dia is related to a cardiac event rate of 8%/year compared
with only 1 .5%/year among those without ventricular tachy-
cardia. However, nonsustained ventricular tachycardia is a
relatively nonspecific finding, seen on Holter recording in
approximately 20% to 50% of adult patients with hypertro-
phic cardiomyopathy, most of whom have no subsequent
cardiac event over the subsequent 3 years (4,8) . Ten percent
to 77% of adult patients with hypertrophic cardiomyopathy
and sudden death ~lave inducible sustained ventricular ar-
rhythmia on programmed stimulation as do approximately
50% of patients with syncope. These findings are favored by
the presence of large areas of fibrosis separating myocardial
strips (4) . Yet specific effective antiarrhythmic treatment has
not been found and, obviously, absence of ventricular ar-
rhythmia does not safeguard against sudden death . In the
study of Dilsizian et al . (1), only 3 of 15 selected young
patients with hypertrophic cardiomyopathy and cardiac ar-
rest or syncope had ventricular tachycardia on ambulatory
ECG recording, and the arrhythmia was inducible on elec-
trophysiologic study in only 4 of these 15 .
in the young . These relationships appear even less se-
cure in the young, in whom hypertrophic cardiomyopathy is
associated with a poor prognosis and a mortality rate of
-50% within 9 years of diagnosis (2,15) . In these patients,
age itself (2,! 1), along with presenting symptoms and a
family history of sudden death serves as a marker of contin-
ued catastrophe . Ventricular arrhythmia on ambulatory
ECG recording occurs with reduced frequency among those
with prior cardiac arrest (9,15) . This evidence suggests that
the mechanisms of syncope and sudden death may be
different in the young with hypertrophic cardiomyopathy .
Myocardial ischemia has long been incriminated in hf-
pertrophic cardiomyopathy and has been thought tc, play a
role in both its symptomatic presentation and course (8)
.
Chest pain and ECG changes suggestive of ischemia are
prominently seen in adults, and evidence suggests that they
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806
BOTVINICK ET AL.
EDITORIAL COMMENT
occur in young patients with this condition as well (16-18) .
Is myocardial ischemia the underlying cause of syncope and
sudden death in hypertrophic cardiomyopathy? According
to the data presented by Dilsizian and coworkers (1), this
relationship may be particularly valid in the young .
Seinti phic studies. Several workers have documented
the frequent occurrence of exercise-induced myocardial
perfusion abnormalities on planar and single-photon emis-
sion computed tomography (SPECT) perfusion scintigraphic
study in adults with hypertrophic cardiomyopathy (17) . Prior
work by the coworkers of Dilsizian (19) has promised a
protective effect of medical treatment. In some studies,
reversible perfusion defects were related to a history of
dyspnea and fatigue rather than to chest pain . Positive
perfusion images were noted to be a unique prognostic index
related to the occurrence of ventricular tachycardia
(16.17,19) in patients whose perfusion abnormalities were
iocalized to regions of normal thickness and apparently
greatest regional wall stress (20) .
The demonstration of a similar frequency of reversible
scintigraphic abnormalities among symptomatic and asymp-
tomatic patients with hypertrophic cardiomyopathy raised
the question of a possible relationship between these abnor-
malities and altered cellular thallium-201 kinetics in these
patients, rather than to induced icchemia (18) . However,
similar perfusion defects were noted on studies performed
with technetium-99m sestamibi, which localizes by a mech-
anism totally different from that of the sodium-potassium-
adenosine triphosphatase transmembrane pump that drives
thallium-201(21). Additionally, the findings of exertional or
pacing-induced chest pain and ST segment depression or
pacing-induced abnormalities of diastolic compliance and
metabolism in patients with hypertrophic cardiomyopathy
and reversible perfusion defects support their relation to
ischemia (18) . In the study by Dilsizian and coworkers (1),
scintigraphic evidence of ischemia was very frequent among
a select group of young patients with hypertrophic cardio-
myopathy with syncope or sudden cardiac death, but much
less frequent among asymptomatic patients .
RJatlonship between
induced ischemia and sudden death .
Prior studies have demonstrated that clinical ventricular
tachycardia most frequently occurs in patients with chronic
coronary artery disease with extensively scarred ventricles
(20) and the electrophysiologic milieu to support arrhythmia .
Such arrhythmia is not generally associated with ongoing
ischemia, It is often inducible on programmed electrical
stimulation, and scintigraphy generally demonstrates fixed,
not reversible perfusion abnormalities in patients witl : such
arrhythmia. However, patients with coronary artery disease
and a clinical history of ventricular tachycardia often have
no inducible arrhythmia and are thought to require an
additional condition, such as ischemia, to stimulate their
arrhythmia. These patients most often demonstrate revers-
ible perfusion abnormalities and, in such patients, reperfu-
sion therapy might have beneficial effects on arrhythmia
suppression
. Fixed abnormalities on scintigraphic studies
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performed in adult patients with hypertrophic cardiomyop-
athy are often associated with inducibility of ventricular
tachycardia on electrophysiologic study, which suggests an
unlikely role for ischemia . However, drawing the parallel
t:
rom coronary disease, the infrequency of arrhythmia induc-
ibility in young patients with hypertrophic cardiomyopathy
and the frequency and extent of related stress-induced
scintigraphic and ECG evidence of ischemia add further
support to the suggestion that many sudden deaths of
arrhythmic and other origin could indeed be related to a
necessary underlying ischemic condition .
Mechanisms of ischemia. A multitude of mechanisms
affecting both coronary demand and supply, many of which
are common to left ventricular hypertrophy in general, may
potentially contribute to the ischemic outcome . These in-
clude augmented myocardial oxygen demands related to
increased muscle mass ; frequent outflow obstruction (18) ;
reduced diastolic compliance and increased wall stress-,
increased resistance to diastolic coronary flow and systolic
compression ; abnormal reactivity of the coronary arterioles
and precapillaries with reduced flow reserve (22), addition-
ally limited by anatomic abnormalities of these vessels (23)
and possible spasm, as well as the documented reduction of
coronary capillary density, all aggravated by tachycardia
and a shortened time in diastole . Some of these have already
been related to markers of stress-induced ischemia (22) .
Recently the genetic defect has been isolated in some
families and the nature of this abnormality may itself affect
myosin structure, possibly requiring adaptation with hyper-
trophy, influencing survival (24) . Finally, this ischemic leg-
acy may be the culprit responsible for the variable amount of
myocardial fibrosis, which in turn may present the anatomic
and hater electrophysiologic substrate for later life-
threatening ventricular arrhythmias and sudden death in
adults with hypertrophic cardiomyopathy . Dilsizian and
coworkers (t) present compelling evidence that ischemia is
often the root cause of syncope and sudden death in young
patients with hypertrophic cardiomyopathy . Further, they
demonstrate the strong, albeit incomplete, protective value
of verapamil (18,23,25,26). Extrapolated over time, this
approach may also have an impact on later arrh~thmia-
related events .
Both our limited experience and the moi d extensive
experience of Dilsizian and coworkers (1) clearly point to an
ischemic mechanism underlying sudden death and syncope,
which occur frequently in young patients with hypertrophic
cardiomyopathy. The demonstrated benefit of specific treat-
ment behooves us to recognize the condition and its specific
threat, and to treat it aggressively and with respect . Al-
though the pathophysiology of the condition may indeed
differ according to age, we must nonetheless continue to
seek this ischemic cause in adults with hypertrophic cardio-
myopathy as well . As with hypertrophic cardiomyopathy in
childhood, new methods addressed to a specific question by
persistent investigators may identify clinically important
mechanisms of disease .
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